-
Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled TrialK Kanenawa, K Yamaji, H Tashiro et al. -
DAPT, Our Genome and ClopidogrelPeter C. Block, M.D., FACC
-
Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trialColombo A, Chieffo A, Frasheri A et al.
-
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT SubstudyLee BK, Kim JS, Lee OH et al.
-
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical TrialB-K Kim, S-J Hong, TICO Investigators et al.
-
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trialHelft G, Steg PG, OPTImal DUAL Antiplatelet Therapy Trial Investigators.
-
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trialValgimigli M, Campo G, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators.
-
Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE TrialY Park, JH Kim, TH Kim et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
